Skip to main content
The Markets by Proactive
Go to Proactive Australia

Archive

Emyria advances cannabinoid and MDMA-analogue development with $3 million cap raise

Emyria advances cannabinoid and MDMA-analogue development with $3 million cap raise

Emyria Ltd (ASX:EMD) managing director Michael Winlow joins Proactive to highlight the success of a recent $3 million capital raise, which the company intends to leverage for cannabinoid registration and MDMA-analogue development. Cornerstone investor Tattarang’s Tenmile Ventures – a biotech-centred fund – and lead manager Sixty-Two Capital both made large contributions to the raise.

ASX #ProactiveInvestors #Emyria #MDMA #Cannabinoids #Biotech